The major mTOR inhibitors, everolimus and temsirolimus, have fared poorly as single agents in MM trials [199,200], while the few myeloma-based trials that have included mTOR blockers in various combinations heretofore have not produced published results. The gene discussed is MTOR; the disease is plasma cell myeloma.